We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Danaher Corporation | NYSE:DHR | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.78 | -0.32% | 246.04 | 246.89 | 244.28 | 246.50 | 2,075,871 | 20:50:27 |
From Apr 2019 to Apr 2024
By Dave Sebastian
Danaher Corp. said it expects core revenue, including Cytiva, to grow in the mid to high-teens range in the first quarter, as it reported lower profit and higher sales for the fourth quarter.
The conglomerate said it expects core revenue, including Cytiva, to grow by low-double digits for the full year.
Danaher acquired Cytiva, a life sciences company, in 2020.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
January 28, 2021 06:40 ET (11:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Danaher Chart |
1 Month Danaher Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
